COVID-19 alters thinking and management in metabolic diseases
- 25 November 2020
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 17 (2) , 71-72
Abstract
Metabolic diseases emerged as important risk factors for severe COVID-19, but the mechanisms responsible remained unclear for some time. The severity of metabolic diseases was also associated with worse outcomes in patients with COVID-19, forcing clinicians to adjust their thinking on which patients with metabolic disease, but without COVID-19, to prioritize for treatment during and immediately after the pandemic.Keywords
This publication has 10 references indexed in Scilit:
- Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population studyThe Lancet Diabetes & Endocrinology, 2020
- Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial VaginosisNew England Journal of Medicine, 2020
- COVID-19: a hypothesis regarding the ventilation-perfusion mismatchCritical Care, 2020
- Prevalence of obesity among adult inpatients with COVID-19 in FranceThe Lancet Diabetes & Endocrinology, 2020
- Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19New England Journal of Medicine, 2020
- The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infectionCritical Care, 2020
- High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical VentilationObesity, 2020
- Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19New England Journal of Medicine, 2020
- COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgeryThe Lancet Diabetes & Endocrinology, 2020